Sermorelin + Ipamorelin: Stack, Ingredients, Research & BAC Water Concentration
What is the Sermorelin + Ipamorelin stack? It is a two-peptide combination containing the GHRH analogue sermorelin and the growth-hormone secretagogue ipamorelin. The two compounds act through related but distinct signaling pathways involved in growth-hormone secretion. However, a commercially encountered blend should not be confused with a clinically standardized combination: the mass ratio, vial strength and compounded presentation can vary by source.
Research-use clarification: This page explains published research, formulation terminology and concentration mathematics. It does not establish a treatment protocol, recommended human dose, or evidence that combining the two compounds is safe or effective. Individual-component evidence must not be interpreted as evidence for the complete combination.
Sermorelin + Ipamorelin Stack Snapshot
Common Name
Sermorelin + Ipamorelin
Components
Sermorelin + Ipamorelin
Commonly Encountered Blend
5 mg + 5 mg
Standardized Formulation?
No universal standard
Human Combination Evidence
Limited / no controlled combination trial identified
Combined Research Vial Example formulation: 5 mg Sermorelin + 5 mg Ipamorelin
What Is the Sermorelin + Ipamorelin Stack?
Sermorelin + Ipamorelin refers to a two-compound peptide combination in which sermorelin represents a growth-hormone-releasing-hormone pathway and ipamorelin represents a growth-hormone secretagogue pathway. Both have been investigated separately, but the existence of research on each component does not establish the clinical efficacy or safety of the combined formulation.
In market and compounding contexts, the combination is encountered in multiple strengths. FDA materials discussing compounded products have documented combinations containing sermorelin and ipamorelin, including examples reported at 1.5 mg/mL and a separate 5 mg + 5 mg compounded presentation. This demonstrates that the name does not identify one universally fixed formulation.
Is “Sermorelin + Ipamorelin” a Standardized Clinical Formulation?
Short answer: No universal standardized formulation should be assumed.
“Sermorelin + Ipamorelin” describes the ingredients rather than automatically identifying one pharmaceutical product, fixed ratio, vial strength or validated clinical protocol.
When a source lists a formulation such as 5 mg Sermorelin + 5 mg Ipamorelin, that specific mass composition should be treated as the composition of that particular vial or product—not as a universal definition of the stack.
What's in Sermorelin + Ipamorelin?
01
Sermorelin
GHRH analogue29 amino acidsGHRH receptor
Sermorelin is a synthetic analogue corresponding to the biologically active N-terminal portion of human growth hormone-releasing hormone (GHRH). It has been studied for stimulating endogenous growth hormone secretion and historically investigated in growth-hormone deficiency.
Human studies of GHRH(1–29)/sermorelin include research in children with growth-hormone deficiency and diagnostic stimulation studies.
02
Ipamorelin
GH secretagogueGHS-R pathwayPentapeptide
Ipamorelin is a synthetic growth-hormone secretagogue that has been investigated for its ability to stimulate growth-hormone release. Its pharmacology differs from sermorelin because it acts through the growth-hormone secretagogue receptor pathway.
Human volunteer research has examined ipamorelin pharmacokinetics and pharmacodynamics and demonstrated dose-related effects on growth-hormone release.
Why Are Sermorelin and Ipamorelin Combined?
The scientific rationale for studying the pair comes from their different mechanisms within growth-hormone regulation. Sermorelin activates the GHRH side of the somatotropic axis, whereas ipamorelin is a growth-hormone secretagogue acting through GHS-R signaling.
This mechanistic complementarity provides a rationale for laboratory investigation, but mechanistic plausibility is not clinical evidence. A theoretical interaction does not prove that a particular ratio, concentration, or combined product improves outcomes or has an acceptable safety profile.
Evidence for Each Component
Sermorelin Evidence
Individual evidence
Published human research has evaluated sermorelin/GHRH(1–29) in growth-hormone deficiency and related endocrine investigations. One multicenter study evaluated once-daily GHRH(1–29) in prepubertal children with growth-hormone deficiency and reported increased height velocity during treatment.
A review of sermorelin research describes its use in diagnosis and historical treatment investigations involving growth-hormone deficiency.
Evidence interpretation: These studies provide information about sermorelin itself. They do not validate a sermorelin + ipamorelin combination.
Ipamorelin Evidence
Individual evidence
Ipamorelin has been studied in humans for pharmacokinetics and pharmacodynamics. A dose-escalation study in healthy male volunteers characterized ipamorelin exposure and growth-hormone responses.
Earlier pharmacological research characterized ipamorelin as a selective growth-hormone secretagogue and investigated its endocrine effects.
Evidence interpretation: Human ipamorelin research should be kept separate from evidence for a fixed sermorelin + ipamorelin blend.
Has the Complete Sermorelin + Ipamorelin Combination Been Clinically Studied?
The complete Sermorelin + Ipamorelin combination should not be described as a clinically validated fixed formulation.
Published evidence identified for this page includes human studies of the individual compounds, while available evidence does not establish a controlled human clinical trial validating a specific combined Sermorelin + Ipamorelin vial formulation, ratio, concentration or therapeutic protocol.
This distinction is important: evidence that sermorelin can stimulate growth-hormone secretion and evidence that ipamorelin can stimulate growth-hormone secretion do not prove that the combination is more effective, safer, or clinically appropriate.
Individual component
Sermorelin
Human research exists.
Individual component
Ipamorelin
Human pharmacology research exists.
Complete combination
Sermorelin + Ipamorelin
No standardized, clinically validated combination formulation should be inferred from individual-component studies.
Market / compounding
Commercial formulations
Multiple formulations are encountered, including 5 mg + 5 mg presentations and other compounded concentrations.
Common Sermorelin + Ipamorelin Formulations
The following examples illustrate formulations encountered in research and compounding contexts. They are not presented as interchangeable or universally standardized formulations.
Formulation example
Sermorelin
Ipamorelin
Interpretation
5 mg / 5 mg blend
5 mg
5 mg
1:1 mass ratio; commonly encountered research presentation
1.5 mg / 1.5 mg per mL
1.5 mg/mL
1.5 mg/mL
Example of a compounded concentration documented in FDA materials
Other compounded formats
Variable
Variable
Composition must be verified from the specific product documentation
Important: The label “Sermorelin + Ipamorelin” does not by itself establish a particular mass ratio. Always identify the actual amount of each component in the specific vial before performing concentration calculations.
For a two-component vial, the correct mathematical approach is to calculate the concentration of each component separately. Both components share the same final liquid volume, but each retains its own mass.
Example Research Vial
Assume a hypothetical vial contains:
Sermorelin: 5 mg
Ipamorelin: 5 mg
Total peptide mass: 10 mg
Component concentration (mg/mL) = component mass (mg) ÷ final liquid volume (mL)
Therefore, if the final liquid volume were 2 mL:
Sermorelin = 5 mg ÷ 2 mL = 2.5 mg/mL Ipamorelin = 5 mg ÷ 2 mL = 2.5 mg/mL
Do not calculate: 10 mg ÷ 2 mL = 5 mg/mL and then call that the concentration of each peptide. The 5 mg/mL figure represents the combined peptide mass per mL, not the concentration of either individual component.
Increasing the final liquid volume decreases the concentration of both components proportionally. The amount of each peptide in the vial does not change simply because the liquid volume changes.
1 mL
Sermorelin: 5 mg/mL Ipamorelin: 5 mg/mL
2 mL
Sermorelin: 2.5 mg/mL Ipamorelin: 2.5 mg/mL
3 mL
Sermorelin: 1.667 mg/mL Ipamorelin: 1.667 mg/mL
5 mL
Sermorelin: 1 mg/mL Ipamorelin: 1 mg/mL
How BAC-Water Volume Changes Every Component's Concentration
Example 1 — 1 mL Final Volume
Sermorelin: 5 mg ÷ 1 mL = 5 mg/mL Ipamorelin: 5 mg ÷ 1 mL = 5 mg/mL
Example 2 — 3 mL Final Volume
Sermorelin: 5 mg ÷ 3 mL = 1.667 mg/mL Ipamorelin: 5 mg ÷ 3 mL = 1.667 mg/mL
Example 3 — 5 mL Final Volume
Sermorelin: 5 mg ÷ 5 mL = 1 mg/mL Ipamorelin: 5 mg ÷ 5 mL = 1 mg/mL
Key mathematical principle: Adding more liquid does not add more peptide. It increases the final volume, which lowers the concentration of every component according to the same concentration equation.
Need to Calculate Another Vial or BAC-Water Volume?
Use the BacScience Universal BAC Water Calculator for single-compound concentration mathematics. For multi-component blends, calculate each ingredient independently using its own mass and the same final liquid volume.
Why Multi-Component Concentration Calculations Are Different
A single-compound vial can often be represented by one mass and one final volume. A multi-component vial requires a separate calculation for each component.
Calculation approach
Correct?
Why?
5 mg Sermorelin ÷ final volume
Yes
Calculates Sermorelin concentration.
5 mg Ipamorelin ÷ final volume
Yes
Calculates Ipamorelin concentration.
10 mg total ÷ final volume
Only for total peptide concentration
Does not represent either component individually.
Assume every “Sermorelin + Ipamorelin” vial is 5/5 mg
No
Market and compounded formulations can vary.
Research Limitations
Human research exists for sermorelin as an individual compound.
Human pharmacological research exists for ipamorelin as an individual compound.
Individual-component evidence does not establish combination efficacy.
Commercial and compounded formulations are not necessarily equivalent.
A 5 mg + 5 mg vial is a formulation example, not a universal clinical standard.
Concentration mathematics does not establish biological potency, stability or clinical suitability.
Reconstitution volume should not be interpreted as a dosing recommendation.
Regulatory & Safety Considerations
Formulation-specific regulatory status matters.
Sermorelin has a historical pharmaceutical and clinical research record, while ipamorelin has primarily been investigated as an experimental growth-hormone secretagogue. The regulatory status of a particular compounded or research formulation depends on the jurisdiction, source, intended use and product status.
A research blend should not be presented as an FDA-approved combination product merely because both individual compounds have been studied in humans.
Research-use boundary: This page is a scientific reference for formulation terminology, published evidence and concentration calculations. It does not provide a human treatment regimen, dosing schedule, injection instructions or medical recommendation.
Sermorelin + Ipamorelin FAQ
What is Sermorelin + Ipamorelin?
Sermorelin + Ipamorelin is a two-peptide combination containing a GHRH analogue and a growth-hormone secretagogue. The combination is encountered in research and compounding contexts, but it should not automatically be treated as one standardized pharmaceutical formulation.
Is Sermorelin + Ipamorelin a standardized formulation?
No universal formulation should be assumed. Different sources may use different component amounts, concentrations and vial formats. The actual product documentation should be used for mathematical calculations.
What is a common Sermorelin + Ipamorelin blend?
A 5 mg Sermorelin + 5 mg Ipamorelin presentation is commonly encountered in the research market. It represents a 1:1 mass ratio, but it should not be treated as the universal definition of the combination.
How much BAC water is needed for Sermorelin + Ipamorelin?
There is no single universal volume that defines the combination. The mathematical concentration depends on the mass of each component and the final liquid volume. For example, a 5 mg + 5 mg vial produces 2.5 mg/mL of each component at a 2 mL final volume, while a 5 mL final volume produces 1 mg/mL of each component. These examples explain concentration mathematics rather than prescribing a reconstitution protocol.
Does adding more BAC water reduce the amount of peptide?
No. Assuming no material loss, the mass of each peptide remains the same while the final volume increases. Therefore, the concentration decreases.
Can I combine the two peptide masses before calculating concentration?
Only if you specifically want the total peptide concentration. For example, 5 mg + 5 mg equals 10 mg total peptide. However, 10 mg divided by the final volume does not tell you the individual Sermorelin or Ipamorelin concentration.
Has the complete Sermorelin + Ipamorelin stack been clinically validated?
Individual human research exists for the two compounds, but this should not be interpreted as clinical validation of a fixed Sermorelin + Ipamorelin combination. A particular commercial blend and ratio requires combination-specific evidence.
Does evidence for Sermorelin prove that the combination works?
No. Evidence for Sermorelin concerns Sermorelin. Evidence for Ipamorelin concerns Ipamorelin. Combination efficacy and safety require evidence studying the combination itself.
Is a 5 mg + 5 mg vial always the same?
The stated mass composition may be the same, but researchers should still verify identity, purity, actual content, formulation details and batch documentation for the specific vial.
What calculator should I use for BAC-water concentration?
The BacScience Universal BAC Water Calculator is useful for concentration mathematics. For a multi-component vial, perform the calculation separately for every component rather than treating the blend as one compound.
Background on bacteriostatic water and benzyl alcohol.
Scientific References
Ipamorelin pharmacokinetic/pharmacodynamic study in healthy human volunteers. PubMed PMID: 10496658.
Sermorelin/GHRH(1–29) treatment research in children with growth-hormone deficiency. PubMed PMID: 8772599.
Review of sermorelin use in diagnosis and treatment of childhood growth-hormone deficiency. PubMed PMID: 18031173.
Pharmacological characterization of ipamorelin as a selective growth-hormone secretagogue. PubMed PMID: 9849822.
FDA Pharmacy Compounding Advisory Committee materials documenting reported compounded products containing ipamorelin and sermorelin.
Last reviewed: September 11, 2026 Evidence classification: Individual-component research / formulation and concentration reference / combination evidence assessment.
Choosing a selection results in a full page refresh.
